Guide
Semaglutide Cost in 2026: Every Route, With Its Evidence Grade
Compounded semaglutide runs $145 to $178 a month on figures we read at source. Brand Wegovy is $349 through NovoCare, the approved oral tablet is $149, and Ozempic lists
Compounded semaglutide runs $145 to $178 a month on figures we read at source. Brand Wegovy is $349 through NovoCare, the approved oral tablet is $149, and Ozempic lists near $998. With commercial coverage a copay of $0 to $25 is common, and eligible Medicare enrollees pay about $50 through the GLP-1 Bridge.
What does each route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial coverage plus savings card | $0–$25 | $0–$300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $145 | $1,740 | Captured at source |
| Oral Wegovy tablet, self-pay | $149 | $1,788 | Provider-reported |
| Compounded, month-to-month, flat | $165 | $1,980 | Captured at source |
| Compounded plus membership | $178 | $2,136 | Captured at source |
| Brand Wegovy, NovoCare | $349 | $4,188 | Provider-reported |
| Brand Ozempic, retail cash | ~$998 | ~$11,976 | Third-party claim |
Only the captured rows were read on the provider's own page by us, with a date. See our evidence grades for what each label means.
The cheapest compounded programme we captured is $145. The approved oral Wegovy tablet is $149. Four dollars a month separates an unapproved preparation from an FDA-approved product with its own trial programme.
That is a reversal from two years ago, and it is the single most useful fact for anyone shopping on price alone.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Does the price change as the dose goes up?
Semaglutide titrates over roughly 16 to 20 weeks: 0.25 mg for four weeks, then 0.5, 1.0, 1.7 and 2.4 mg. A programme that prices by dose collects its advertised figure for about one month.
| Protocol | Monthly | 3-month | 6-month | 12-month | Flat at every dose? |
|---|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab), regular injectable | $165 | $149 | $147 | $145 | Yes |
| NexLife (opens nexlife.us in a new tab), microdose | $129 | $117 | $114 | $110 | Yes |
| NexLife (opens nexlife.us in a new tab), sublingual ODT | $199 | $185 | $177 | $165 | Yes |
| Mochi Health, all-in | $178 | — | — | — | Yes, but $99 + $79 membership |
Plan totals as published: $447 for three months, $882 for six, $1,740 for twelve. Each reconciles exactly against its monthly rate. The sublingual 3-month plan does not — it states a $597 total against a $185 monthly rate, which multiplies to $555. We record the monthly rate and have asked for the total to be corrected. COR-012.
The captured programmes above are flat across the full range, so the advertised figure is also the maintenance figure. That is rarer than the marketing language suggests: we record a rate as flat only where the provider states it on its own page and we archived it with a date.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. A salt form is a different chemical entity; it has not been through the safety or efficacy review the base went through.
Ask for the exact salt form and concentration in writing before you buy. A provider that cannot answer in writing has told you something. There is no tirzepatide equivalent of this question, which is why it belongs on every semaglutide page and on none of the tirzepatide ones.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How much does semaglutide cost per month?
Compounded runs $145 to $178 on figures we captured at source. Brand Wegovy is $349 through NovoCare, the approved oral tablet $149, and Ozempic lists near $998.
Is compounded semaglutide cheaper than the approved pill?
By about $4 a month. $145 compounded against $149 for the oral Wegovy tablet, which carries its own trial evidence.
Does semaglutide cost more at higher doses?
On dose-tiered programmes, yes. The captured programmes on this page are flat across the full 0.25 to 2.4 mg range.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- Semaglutide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- GLP-1 Telehealth vs Local Weight-Loss ClinicComparisons
- GLP-1 Data API DocumentationData
Related coverage
Semaglutide Ranked. “Semaglutide Cost in 2026: Every Route, With Its Evidence Grade.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/semaglutide-cost-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.